Cancer Immunology, Immunotherapy

, Volume 58, Issue 1, pp 71–84

Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity

  • Dina Preise
  • Roni Oren
  • Itai Glinert
  • Vyacheslav Kalchenko
  • Steffen Jung
  • Avigdor Scherz
  • Yoram Salomon
Original Article

Abstract

Vascular-targeted photodynamic therapy (VTP) takes advantage of intravascular excitation of a photosensitizer (PS) to produce cytotoxic reactive oxygen species (ROS). These ROS are potent mediators of vascular damage inducing rapid local thrombus formation, vascular occlusion, and tissue hypoxia. This light-controlled process is used for the eradication of solid tumors with Pd-bacteriochlorophyll derivatives (Bchl) as PS. Unlike classical photodynamic therapy (PDT), cancer cells are not the primary target for VTP but instead are destroyed by treatment-induced oxygen deprivation. VTP initiates acute local inflammation inside the illuminated area accompanied by massive tumor tissue death. Consequently, in the present study, we addressed the possibility of immune response induction by the treatment that may be considered as an integral part of the mechanism of VTP-mediated tumor eradication. The effect of VTP on the host immune system was investigated using WST11, which is now in phase II clinical trials for age-related macular degeneration and intended to be evaluated for cancer therapy. We found that a functional immune system is essential for successful VTP. Long-lasting systemic antitumor immunity was induced by VTP involving both cellular and humoral components. The antitumor effect was cross-protective against mismatched tumors, suggesting VTP-mediated production of overlapping tumor antigens, possibly from endothelial origin. Based on our findings we suggest that local VTP might be utilized in combination with other anticancer therapies (e.g., immunotherapy) for the enhancement of host antitumor immunity in the treatment of both local and disseminated disease.

Keywords

Bachteriochlorophyll Cancer Immune response Immunotherapy Photodynamic therapy Vascular targeting 

References

  1. 1.
    Adam JK, Odhav B, Bhoola KD (2003) Immune responses in cancer. Pharmacol Ther 99:113–132PubMedCrossRefGoogle Scholar
  2. 2.
    Agaiby AD, Dyson M (1999) Immuno-inflammatory cell dynamics during cutaneous wound healing. J Anat 195(Pt 4):531–542PubMedCrossRefGoogle Scholar
  3. 3.
    Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18:767–811PubMedCrossRefGoogle Scholar
  4. 4.
    Boumedine RS, Roy DC (2005) Elimination of alloreactive T cells using photodynamic therapy. Cytotherapy 7:134–143PubMedCrossRefGoogle Scholar
  5. 5.
    Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998–1008PubMedGoogle Scholar
  6. 6.
    Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6:535–545PubMedCrossRefGoogle Scholar
  7. 7.
    Chen WR, Huang Z, Korbelik M, Nordquist RE, Liu H (2006) Photoimmunotherapy for cancer treatment. J Environ Pathol Toxicol Oncol 25:281–291PubMedGoogle Scholar
  8. 8.
    Diegelmann RF, Evans MC (2004) Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 9:283–289PubMedCrossRefGoogle Scholar
  9. 9.
    Dolmans DE, Fukumura D, Jain RK (2003) Photodynamic therapy for cancer. Nat Rev Cancer 3:380–387PubMedCrossRefGoogle Scholar
  10. 10.
    Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q (1998) Photodynamic therapy. J Natl Cancer Inst 90:889–905PubMedCrossRefGoogle Scholar
  11. 11.
    Elmets CA, Bowen KD (1986) Immunological suppression in mice treated with hematoporphyrin derivative photoradiation. Cancer Res 46:1608–1611PubMedGoogle Scholar
  12. 12.
    Felicetti P, Mennecozzi M, Barucca A, Montgomery S, Orlandi F, Manova K, Houghton AN, Gregor PD, Concetti A, Venanzi FM (2007) Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag. Cytotherapy 9:23–34CrossRefGoogle Scholar
  13. 13.
    Gollnick SO, Owczarczak B, Maier P (2006) Photodynamic therapy and anti-tumor immunity. Laser Surg Med 38:509–515CrossRefGoogle Scholar
  14. 14.
    Gollnick SO, Vaughan L, Henderson BW (2002) Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 62:1604–1608PubMedGoogle Scholar
  15. 15.
    Gross S, Gilead A, Scherz A, Neeman M, Salomon Y (2003) Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 9:1327–1331PubMedCrossRefGoogle Scholar
  16. 16.
    Habib Moinuddin S, Ali R (2006) Peroxinitrite modified DNA: a better antigen for systemic lupus erythematosus anti-DNA autoantibodies. Biotechnol Appl Biochem 43(Pt 2):65–70CrossRefGoogle Scholar
  17. 17.
    Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT, Morgan J (2004) Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 64:2120–2126PubMedCrossRefGoogle Scholar
  18. 18.
    Houghton AN, Guevara-Patino JA (2004) Immune recognition of self in immunity against cancer. J Clin Invest 114:468–471PubMedGoogle Scholar
  19. 19.
    Jalili A, Makowski M, Switaj T, Nowis D, Wilczynski GM, Wilczek E, Chorazy-Massalska M, Radzikowska A, Maslinski W, Bialy L, Sienko J, Sieron A, Adamek M, Basak G, Mroz P, Krasnodebski IW, Jakobisiak M, Golab J (2004) Effective photoimmunotherapy of murine colon carcinoma induced by the combination of photodynamic therapy and dendritic cells. Clin Cancer Res 10:4498–4508PubMedCrossRefGoogle Scholar
  20. 20.
    Jolles CJ, Ott MJ, Straight RC, Lynch DH (1988) Systemic immunosuppression induced by peritoneal photodynamic therapy. Am J Obstet Gynecol 158:1446–1453PubMedGoogle Scholar
  21. 21.
    Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F, Pamer EG, Littman DR, Lang RA (2002) In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17:211–220PubMedCrossRefGoogle Scholar
  22. 22.
    Kasprzyk PG, Song SU, Di Fiore PP, King CR (1992) Therapy of an animal model of human gastric cancer using a combination of anti-erbB–2 monoclonal antibodies. Cancer Res 52:2771–2776PubMedGoogle Scholar
  23. 23.
    Korbelik M (2006) PDT-associated host response and its role in the therapy outcome. Laser Surg Med 38:500–508CrossRefGoogle Scholar
  24. 24.
    Korbelik M, Cecic I (1999) Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 137:91–98PubMedCrossRefGoogle Scholar
  25. 25.
    Korbelik M, Dougherty GJ (1999) Photodynamic therapy-mediated immune response against subcutaneous mouse tumors. Cancer Res 59:1941–1946PubMedGoogle Scholar
  26. 26.
    Korbelik M, Sun J, Cecic I (2005) Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res 65:1018–1026PubMedGoogle Scholar
  27. 27.
    Koudinova NV, Pinthus JH, Brandis A, Brenner O, Bendel P, Ramon J, Eshhar Z, Scherz A, Salomon Y (2003) Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer 104:782–789PubMedCrossRefGoogle Scholar
  28. 28.
    Kousis PC, Henderson BW, Maier PG, Gollnick SO (2007) Photodynamic therapy enhancement of antitumor immunity is regulated by neutrophils. Cancer Res 67:10501–10510PubMedCrossRefGoogle Scholar
  29. 29.
    Lynch DH, Haddad S, King VJ, Ott MJ, Straight RC, Jolles CJ (1989) Systemic immunosuppression induced by photodynamic therapy (PDT) is adoptively transferred by macrophages. Photochem Photobiol 49:453–458PubMedCrossRefGoogle Scholar
  30. 30.
    Macdonald IJ, Dougherty GJ (2001) Basic principles of photodynamic therapy. J Porphyrins Phthalocyanines 5:105–129CrossRefGoogle Scholar
  31. 31.
    Mazor O, Brandis A, Plaks V, Neumark E, Rosenbach-Belkin V, Salomon Y, Scherz A (2005) WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model. Photochem Photobiol 81:342–351PubMedCrossRefGoogle Scholar
  32. 32.
    Musser DA, Fiel RJ (1991) Cutaneous photosensitizing and immunosuppressive effects of a series of tumor localizing porphyrins. Photochem Photobiol 53:119–123PubMedCrossRefGoogle Scholar
  33. 33.
    Nowis D (2005) The influence of photodynamic therapy on the immune response. Photodiagn Photodyn Ther 2:283–298CrossRefGoogle Scholar
  34. 34.
    Ohmori H, Kanayama N (2005) Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins. Autoimmun Rev 4:224–229PubMedCrossRefGoogle Scholar
  35. 35.
    Ohmori H, Oka M, Nishikawa Y, Shigemitsu H, Takeuchi M, Magari M, Kanayama N (2005) Immunogenicity of autologous IgG bearing the inflammation-associated marker 3-nitrotyrosine. Immunol Lett 96:47–54PubMedCrossRefGoogle Scholar
  36. 36.
    Preise D, Mazor O, Koudinova N, Liscovitch M, Scherz A, Salomon Y (2003) Bypass of tumor drug resistance by antivascular therapy. Neoplasia 5:475–480PubMedGoogle Scholar
  37. 37.
    Ribas A, Timmerman JM, Butterfield LH, Economou JS (2003) Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol 24:58–61PubMedCrossRefGoogle Scholar
  38. 38.
    Rodeberg DA, Erskine C, Celis E (2007) In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma. J Pediatr Surg 42:1396–1402PubMedCrossRefGoogle Scholar
  39. 39.
    Saji H, Song W, Furumoto K, Kato H, Engleman EG (2006) Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res 12:2568–2574PubMedCrossRefGoogle Scholar
  40. 40.
    Sapoznikov A, Fischer JA, Zaft T, Krauthgamer R, Dzionek A, Jung S (2007) Organ-dependent in vivo priming of naive CD4+, but not CD8+, T cells by plasmacytoid dendritic cells. J Exp Med 204:1923–1933PubMedCrossRefGoogle Scholar
  41. 41.
    Schreiber GJ, Hellstrom KE, Hellstrom I (1992) An unmodified anticarcinoma antibody, BR96, localizes to and inhibits the outgrowth of human tumors in nude mice. Cancer Res 52:3262–3266PubMedGoogle Scholar
  42. 42.
    Sondel PM, Hank JA (2001) Antibody-directed, effector cell-mediated tumor destruction. Hematol Oncol Clin North Am 15:703–721PubMedCrossRefGoogle Scholar
  43. 43.
    St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW (2000) Genes expressed in human tumor endothelium. Science 289:1197–1202PubMedCrossRefGoogle Scholar
  44. 44.
    Thong PS, Ong KW, Goh NS, Kho KW, Manivasager V, Bhuvaneswari R, Olivo M, Soo KC (2007) Photodynamic-therapy-activated immune response against distant untreated tumours in recurrent angiosarcoma. Lancet Oncol 8:950–952PubMedCrossRefGoogle Scholar
  45. 45.
    Valamanesh F, Berdugo M, Bejjani RA, Savoldelli M, Jeanny JC, Brun PH, Blanc D, Ben-Ezra D, Behar-Cohen F (2004) Reduced collateral effect of photodynamic therapy (PDT) using a new water soluble photosensitizing agent. Invesr Ophthalmol Vis Sci 45:Google Scholar
  46. 46.
    van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH, Griffioen AW (2006) Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 108:2339–2348PubMedCrossRefGoogle Scholar
  47. 47.
    van Duijnhoven FH, Tollenaar RA, Terpstra OT, Kuppen PJ (2005) Locoregional therapies of liver metastases in a rat CC531 coloncarcinoma model results in increased resistance to tumour rechallenge. Clin Exp Metastasis 22:247–253PubMedCrossRefGoogle Scholar
  48. 48.
    Wuttge DM, Bruzelius M, Stemme S (1999) T-cell recognition of lipid peroxidation products breaks tolerance to self proteins. Immunology 98:273–279PubMedCrossRefGoogle Scholar
  49. 49.
    Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL (1994) Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 14:32–40PubMedGoogle Scholar
  50. 50.
    Yusuf N, Katiyar SK, Elmets CA (2008) The immunosuppressive effects of phthalocyanine photodynamic therapy in mice are mediated by CD4(+) and CD8(+) T cells and can be adoptively transferred to naive recipients. Photochem Photobiol 84:366–370PubMedCrossRefGoogle Scholar
  51. 51.
    Zilberstein J, Schreiber S, Bloemers MC, Bendel P, Neeman M, Schechtman E, Kohen F, Scherz A, Salomon Y (2001) Antivascular treatment of solid melanoma tumors with bacteriochlorophyll-serine-based photodynamic therapy. Photochem Photobiol 73:257–266PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Dina Preise
    • 1
  • Roni Oren
    • 1
  • Itai Glinert
    • 1
  • Vyacheslav Kalchenko
    • 4
  • Steffen Jung
    • 3
  • Avigdor Scherz
    • 2
  • Yoram Salomon
    • 1
  1. 1.Department of Biological RegulationThe Weizmann Institute of ScienceRehovotIsrael
  2. 2.Department of Plant ScienceThe Weizmann Institute of ScienceRehovotIsrael
  3. 3.Department of Chemical ImmunologyThe Weizmann Institute of ScienceRehovotIsrael
  4. 4.Department of Veterinary ResourcesThe Weizmann Institute of ScienceRehovotIsrael

Personalised recommendations